Successful treatment of essential thrombocythemia with anagrelide in a child

被引：0
|
作者：
Hermann, J
Fuchs, D
Sauerbrey, A
Hempel, L
Zintl, F
机构：
[1] Univ Jena, Dept Pediat, D-6900 Jena, Germany
[2] Univ Jena, Dept Pediat Hematol, D-6900 Jena, Germany
[3] Univ Jena, Dept Oncol, D-6900 Jena, Germany
来源：
MEDICAL AND PEDIATRIC ONCOLOGY | 1998年 / 30卷 / 06期
关键词：
essential thrombocythemia; childhood; anagrelide treatment;
D O I：
10.1002/(SICI)1096-911X(199806)30:6<367::AID-MPO13>3.0.CO;2-F
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：367 / 370
页数：4
相关论文
共 50 条
  • [21] Treatment of Essential Thrombocythemia with Anagrelide Is Associated with an Increased Risk of Worsened Kidney Function
    Kwiatkowski, Jacek
    Kuliszkiewicz-Janus, Malgorzata
    Rymer, Weronika
    Jazwiec, Bozena
    Malecki, Rafal
    PHARMACOLOGY, 2021, 106 (5-6) : 316 - 322
  • [22] GATA1 Is Overexpressed in Patients with Essential Thrombocythemia and It Is Normalized By Anagrelide Treatment
    Brown, Lilia
    Graham, Ciaren
    Martyn, Yvette
    Rinaldi, Ciro
    BLOOD, 2014, 124 (21)
  • [23] Treatment of essential thrombocythemia with anagrelide. A ten-year experience.
    Kornblihtt, LI
    Vassallu, PS
    Heller, P
    Molinas, FC
    MEDICINA-BUENOS AIRES, 2002, 62 (03) : 231 - 236
  • [24] Anagrelide for treatment of essential thrombocythemia (ET): A cost-effectiveness analysis.
    Weinberg, PD
    Golub, RM
    Bennett, CL
    BLOOD, 1998, 92 (10) : 423A - 423A
  • [25] Efficacy and safety of anagrelide in the treatment of essential thrombocythemia: Data from an international registry
    Steurer, M.
    Gisslinger, H.
    Penka, M.
    Sormann, S.
    Schwarz, J.
    Tothova, E.
    Hrubisko, M.
    Hellmann, A.
    Podolak-Dawidziak, M.
    Petrides, P. E.
    ONKOLOGIE, 2011, 34 : 206 - 207
  • [26] SUCCESSFUL TREATMENT OF SUSPECTED ESSENTIAL THROMBOCYTHEMIA IN THE DOG
    SIMPSON, JW
    ELSE, RW
    HONEYMAN, P
    JOURNAL OF SMALL ANIMAL PRACTICE, 1990, 31 (07) : 345 - 348
  • [27] Anagrelide treatment and cardiovascular monitoring in essential thrombocythemia. A prospective observational study
    Tortorella, Giovanni
    Piccin, Andrea
    Tieghi, Alessia
    Marcheselli, Luigi
    Steurer, Michael
    Gastl, Gunther
    Codeluppi, Katia
    Fama, Angelo
    Santoro, Umberto
    Birtolo, Chiara
    Gugliotta, Gabriele
    Cortelazzo, Sergio
    Gugliotta, Luigi
    LEUKEMIA RESEARCH, 2015, 39 (06) : 592 - 598
  • [28] PROGRAM OF SUPPORT TO PATIENTS FOR ADHERENCE (PAAP) TO THE TREATMENT OF ESSENTIAL THROMBOCYTHEMIA (TE) WITH ANAGRELIDE
    Cardenes Dominguez, J. J.
    Ramirez-Ramirez, G.
    Ribera-Casado, J. M.
    Rejas-Muslera, R.
    Plaza-Romero, S.
    HAEMATOLOGICA, 2015, 100 : 197 - 197
  • [29] The Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential Thrombocythemia
    Gunnar Birgegård
    Current Hematologic Malignancy Reports, 2016, 11 : 348 - 355
  • [30] INTERSTITIAL PNEUMONITIS ASSOCIATED WITH ANAGRELIDE IN A PATIENT WITH ESSENTIAL THROMBOCYTHEMIA
    Pascual, A.
    Biedma, A.
    Berruga, J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 604 - 605
12345